Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment through pioneering biologically-based therapies. The company is firmly committed to addressing the pressing challenge of drug resistance in cancer treatment by developing innovative medications that work by reactivating cell death mechanisms.
Cyclacel Pharmaceuticals develops a range of therapeutic candidates aimed at overcoming cancer drug resistance utilizing targeted approaches in cell cycle biology, transcriptional regulation, and mitosis biology. These innovative treatments are designed to tackle cancers that have proven challenging for conventional therapies.
By addressing the mechanisms that allow cancer cells to survive traditional therapies, Cyclacel's medicines aim to enhance treatment efficacy and improve the overall quality of life for patients with cancer and blood-related disorders.
Many patients experience limited treatment options due to cancer drug resistance, leading to the necessity for more effective therapies that can bypass such resistance.